Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $5.50.

A number of research analysts have recently commented on SGMO shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday. Wells Fargo & Company lowered their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday, December 31st. StockNews.com downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Barclays boosted their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, Truist Financial raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Friday, December 13th.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO opened at $1.30 on Tuesday. The firm’s 50 day moving average price is $2.13 and its 200 day moving average price is $1.24. The firm has a market cap of $271.24 million, a P/E ratio of -1.73 and a beta of 1.15. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. During the same quarter in the previous year, the business earned ($0.34) earnings per share. As a group, equities analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.

Institutional Trading of Sangamo Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Meritage Portfolio Management boosted its position in shares of Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 6,740 shares during the period. XTX Topco Ltd lifted its position in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 64,981 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 38,850 shares in the last quarter. Virtu Financial LLC purchased a new position in Sangamo Therapeutics in the 3rd quarter worth approximately $150,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Sangamo Therapeutics in the second quarter valued at approximately $67,000. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.